AAAAAA

   
Results: 1-16 |
Results: 16
A phase II trial of dual protease inhibitor therapy: Amprenavir in combination with indinavir, nelfinavir, or saquinavir
Authors: Eron, JJ Haubrich, R Lang, W Pagano, G Millard, J Wolfram, J Snowden, W Pedneault, L Tisdale, M
Citation: Jj. Eron et al., A phase II trial of dual protease inhibitor therapy: Amprenavir in combination with indinavir, nelfinavir, or saquinavir, J ACQ IMM D, 26(5), 2001, pp. 458-461
A dose-ranging study to evaluate the antiretroviral activity and safety ofamprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience
Authors: Schooley, RT Clumeck, N Haubrich, R Thompson, M Danner, SA van Der Ende, ME Sereni, D Antunes, F Blake, D Myers, RE Tisdale, M Millard, J Mustafa, N Nacci, P
Citation: Rt. Schooley et al., A dose-ranging study to evaluate the antiretroviral activity and safety ofamprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience, ANTIVIR TH, 6(2), 2001, pp. 89-96
Efficacy of zanamivir against avian influenza A viruses that possess genesencoding H5N1 internal proteins and are pathogenic in mammals
Authors: Leneva, IA Goloubeva, O Fenton, RJ Tisdale, M Webster, RG
Citation: Ia. Leneva et al., Efficacy of zanamivir against avian influenza A viruses that possess genesencoding H5N1 internal proteins and are pathogenic in mammals, ANTIM AG CH, 45(4), 2001, pp. 1216-1224
Resistance to the HIV protease inhibitor amprenavir in vitro and in clinical studies - A review
Authors: Tisdale, M Myers, R Randall, S Maguire, M Ait-Khaled, M Elston, R Snowden, W
Citation: M. Tisdale et al., Resistance to the HIV protease inhibitor amprenavir in vitro and in clinical studies - A review, CLIN DRUG I, 20(4), 2000, pp. 267-285
Monitoring of viral susceptibility: new challenges with the development ofinfluenza NA inhibitors
Authors: Tisdale, M
Citation: M. Tisdale, Monitoring of viral susceptibility: new challenges with the development ofinfluenza NA inhibitors, REV MED VIR, 10(1), 2000, pp. 45-55
HIV type 1 protease cleavage site mutations and viral fitness: Implications for drug susceptibility phenotyping assays
Authors: Robinson, LH Myers, RE Snowden, BW Tisdale, M Blair, ED
Citation: Lh. Robinson et al., HIV type 1 protease cleavage site mutations and viral fitness: Implications for drug susceptibility phenotyping assays, AIDS RES H, 16(12), 2000, pp. 1149-1156
Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virologicalevaluation of the AVANTI 2 and AVANTI 3 studies
Authors: Maguire, M Gartland, M Moore, S Hill, A Tisdale, M Harrigan, R Kleim, JP
Citation: M. Maguire et al., Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virologicalevaluation of the AVANTI 2 and AVANTI 3 studies, AIDS, 14(9), 2000, pp. 1195-1201
AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients
Authors: Gartland, M Gerstoft, J Goebel, F Clumeck, N Cooper, DA Gatell, J Gazzard, B Gerstoft, J Goebel, F Lange, J Montaner, J Reiss, P Rozenbaum, W Vella, S Beveridge, A Cooper, DA Duncombe, C Gold, J Haberl, M Clumeck, N Luyts, D Montaner, J Rachlis, A Marina, R Gerstoft, J Wandall, JH Elbrond, B Molina, JM Pialloux, G Rozenbaum, W Beauvais, L Goebel, FD Staszewski, S Bruns, I Hug, M Reiss, P Lange, J Frissen, PHJ van der Ende, ME Bosboom, M Baas, C Milazzo, F Moroni, M Panebianco, R Clotet, B Artigas, JMG Gonzalez-Lahoz, J Leal, M Rodriguez-Lopo, C Gandarias, B Gazzard, B Johnson, M McKinley, S Page, V Watkins, K Sandstrom, E Belsey, E Darbyshire, J Chodakewitz, J Isaacs, R Jonas, L Meibohm, A Coughlan, M Fiddian, P Gartland, M Harrigan, R Larder, B Maguire, M Millard, J Moore, S Patel, K Shortino, D Tisdale, M Vafidis, I Yeo, J
Citation: M. Gartland et al., AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients, AIDS, 14(4), 2000, pp. 367-374
HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy
Authors: Miller, V Ait-Khaled, M Stone, C Griffin, P Mesogiti, D Cutrell, A Harrigan, R Staszewski, S Katlama, C Pearce, G Tisdale, M
Citation: V. Miller et al., HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy, AIDS, 14(2), 2000, pp. 163-171
Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies
Authors: Barnett, JM Cadman, A Gor, D Dempsey, M Walters, M Candlin, A Tisdale, M Morley, PJ Owens, IJ Fenton, RJ Lewis, AP Claas, ECJ Rimmelzwaan, GF De Groot, R Osterhaus, ADME
Citation: Jm. Barnett et al., Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies, ANTIM AG CH, 44(1), 2000, pp. 78-87
Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir
Authors: Markland, W Rao, BG Parsons, JD Black, J Zuchowski, L Tisdale, M Tung, R
Citation: W. Markland et al., Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir, J VIROLOGY, 74(16), 2000, pp. 7636-7641
Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy
Authors: Harrigan, PR Stone, C Griffin, P Najera, I Bloor, S Kemp, S Tisdale, M Larder, B
Citation: Pr. Harrigan et al., Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy, J INFEC DIS, 181(3), 2000, pp. 912-920
Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir
Authors: Buxton, RC Edwards, B Juo, RR Voyta, JC Tisdale, M Bethell, RC
Citation: Rc. Buxton et al., Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir, ANALYT BIOC, 280(2), 2000, pp. 291-300
A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the HIV-1 reverse transcriptase confers high-level cross-resistance to nucleoside reverse transcriptase inhibitors
Authors: Rakik, A Ait-Khaled, M Griffin, P Thomas, DA Tisdale, M Kleim, JP
Citation: A. Rakik et al., A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the HIV-1 reverse transcriptase confers high-level cross-resistance to nucleoside reverse transcriptase inhibitors, J ACQ IMM D, 22(2), 1999, pp. 139-145
In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir
Authors: Barnett, JM Cadman, A Burrell, FM Madar, SH Lewis, AP Tisdale, M Bethell, R
Citation: Jm. Barnett et al., In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir, VIROLOGY, 265(2), 1999, pp. 286-295
Induction of cachexia in mice - reply
Authors: Tisdale, M
Citation: M. Tisdale, Induction of cachexia in mice - reply, BR J CANC, 79(9-10), 1999, pp. 1620-1621
Risultati: 1-16 |